NTLA vs. BMY

In the year-to-date period, NTLA achieves a -28.99% return, which is significantly lower than BMY's -15.29% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NTLA Sharpe Ratio is -0.87, which is lower than the BMY Sharpe Ratio of 0.42. The chart below compares the historical Sharpe Ratios of NTLA and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 5.20%.

The maximum NTLA drawdown since its inception was -96.45%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY. For additional features, visit the drawdowns tool.

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 30.95% compared to Bristol-Myers Squibb Company (BMY) at 10.24%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.